{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:02:43Z","timestamp":1792612963480,"version":"4.5.0"},"reference-count":189,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.critrevonc.2022.103648","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T04:45:23Z","timestamp":1646369123000},"page":"103648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification"],"prefix":"10.1016","volume":"172","author":[{"given":"Hirotaka","family":"Ishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred King-yin","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2022.103648_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217399","article-title":"Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition","volume":"14","author":"Allen","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2022.103648_bib2","doi-asserted-by":"crossref","first-page":"T195","DOI":"10.1530\/ERC-17-0243","article-title":"MEN4 and CDKN1B mutations: the latest of the MEN syndromes","volume":"24","author":"Alrezk","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/MPA.0b013e31825b6acd","article-title":"Glucagon cell adenomatosis without glucagon receptor mutation","volume":"42","author":"Al-Sarireh","year":"2013","journal-title":"Pancreas"},{"key":"10.1016\/j.critrevonc.2022.103648_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/PAS.0b013e3181874eca","article-title":"Insulinomatosis: a multicentric insulinoma disease that frequently causes early recurrent hyperinsulinemic hypoglycemia","volume":"33","author":"Anlauf","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/08830738040190091101","article-title":"Molecular genetic basis of tuberous sclerosis complex: from bench to bedside","volume":"19","author":"Au","year":"2004","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/GIM.0b013e31803068c7","article-title":"Genotype\/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States","volume":"9","author":"Au","year":"2007","journal-title":"Genet. Med."},{"key":"10.1016\/j.critrevonc.2022.103648_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2022.103648_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/MPA.0000000000001189","article-title":"The molecular and clinical landscape of pancreatic neuroendocrine tumors","volume":"48","author":"Batukbhai","year":"2019","journal-title":"Pancreas"},{"key":"10.1016\/j.critrevonc.2022.103648_bib9","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.surg.2007.09.012","article-title":"Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs)","volume":"142","author":"Blansfield","year":"2007","journal-title":"Surgery"},{"key":"10.1016\/j.critrevonc.2022.103648_bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/ERC-18-0494","article-title":"Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia","volume":"26","author":"B\u00f6sch","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10689-019-00152-6","article-title":"Co-occurrence of multiple endocrine neoplasia type 4 and spinal neurofibromatosis: a case report","volume":"19","author":"Brock","year":"2020","journal-title":"Fam. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/jmedgenet-2012-101339","article-title":"High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome","volume":"50","author":"Bubien","year":"2013","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.critrevonc.2022.103648_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085155","article-title":"Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells","volume":"9","author":"Burchett","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2022.103648_bib14","doi-asserted-by":"crossref","first-page":"34221","DOI":"10.18632\/oncotarget.5950","article-title":"Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice","volume":"6","author":"Campesato","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2022.103648_bib15","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in patients with advanced grade 1\/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509)","volume":"39","author":"Capdevila","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib16","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2022.103648_bib17","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1530\/JME-12-0069","article-title":"Molecular pathology and genetics of pancreatic endocrine tumours","volume":"49","author":"Capurso","year":"2012","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000335136","article-title":"Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch","volume":"97","author":"Carter","year":"2013","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.critrevonc.2022.103648_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.401","article-title":"Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading","volume":"8","author":"Cavalcanti","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2022.103648_bib20","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.3390\/ijms21114098","article-title":"p53-PHLDA3-Akt network: the key regulators of neuroendocrine tumorigenesis","volume":"21","author":"Chen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2022.103648_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ando.2020.04.002","article-title":"Multiple endocrine neoplasia type 4: novel CDNK1B variant and immune anomalies","volume":"81","author":"Chevalier","year":"2020","journal-title":"Ann. Endocrinol. ((Paris))"},{"key":"10.1016\/j.critrevonc.2022.103648_bib22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.humpath.2018.07.032","article-title":"ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors","volume":"82","author":"Chou","year":"2018","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.yexmp.2015.08.013","article-title":"Clinical pathological impacts of microRNAs in papillary thyroid carcinoma: a crucial review","volume":"99","author":"Chru\u015bcik","year":"2015","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1046\/j.1365-2265.1997.2861110.x","article-title":"Analysis of the retinoblastoma tumour suppressor gene in pancreatic endocrine tumours","volume":"47","author":"Chung","year":"1997","journal-title":"Clin. Endocrinol. ((Oxf))"},{"key":"10.1016\/j.critrevonc.2022.103648_bib25","first-page":"471","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2022.103648_bib26","doi-asserted-by":"crossref","first-page":"18614","DOI":"10.1038\/s41598-019-55156-0","article-title":"DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors","volume":"9","author":"Cives","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2022.103648_bib27","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1159\/000503721","article-title":"Neuroendocrine neoplasms of the small bowel and pancreas","volume":"110","author":"Clift","year":"2020","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.critrevonc.2022.103648_bib28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fonc.2016.00094","article-title":"Notch signaling in neuroendocrine tumors","volume":"6","author":"Crabtree","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib29","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrg2634","article-title":"Causes and consequences of microRNA dysregulation in cancer","volume":"10","author":"Croce","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.critrevonc.2022.103648_bib30","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/MPA.0000000000001150","article-title":"Characterization of the neuroendocrine tumor immune microenvironment","volume":"47","author":"da Silva","year":"2018","journal-title":"Pancreas"},{"key":"10.1016\/j.critrevonc.2022.103648_bib31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","article-title":"Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs","volume":"68","author":"Dabora","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.critrevonc.2022.103648_bib32","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1186\/s12885-019-6412-8","article-title":"Exploring the current status of neuroendocrine tumours: a population-based analysis of epidemiology, management and use of resources","volume":"19","author":"Darb\u00e0","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib33","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.1038\/onc.2008.229","article-title":"The many facets of Notch ligands","volume":"27","author":"D'Souza","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2022.103648_bib34","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.bjc.6603419","article-title":"A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas","volume":"95","author":"Duran","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1677\/ERC-08-0142","article-title":"Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review","volume":"16","author":"Dworakowska","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152a","author":"Evans","year":"2010","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.critrevonc.2022.103648_bib37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdw561","article-title":"Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study","volume":"28","author":"Faivre","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib38","first-page":"713","article-title":"A phase II study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours","volume":"36","author":"Fazio","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2022.103648_bib39","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1210\/jc.2019-00082","article-title":"Clinical features of multiple endocrine neoplasia type 4: novel pathogenic variant and review of published cases","volume":"104","author":"Frederiksen","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2022.103648_bib40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/jcm9010273","article-title":"Mixed neuroendocrine non-neuroendocrine neoplasms: a systematic review of a controversial and underestimated diagnosis","volume":"9","author":"Frizziero","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2022.103648_bib41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s535-002-8135-x","article-title":"Malignant endocrine tumor of the pancreas associated with von Recklinghausen's disease","volume":"37","author":"Fujisawa","year":"2002","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2022.103648_bib43","series-title":"the WHO Classification of Tumours Editorial Board. WHO Classification of Tumours, 5th Edition, Volume 1: Digestive System Tumours","first-page":"343","article-title":"Pancreatic neuroendocrine neoplasms","author":"Gill","year":"2019"},{"key":"10.1016\/j.critrevonc.2022.103648_bib44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12022-019-9570-y","article-title":"MiRNA-3653 is a potential tissue biomarker for increased metastatic risk in pancreatic neuroendocrine tumours","volume":"30","author":"Gill","year":"2019","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ctrv.2017.04.002","article-title":"Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: a systematic review","volume":"56","author":"Girardi","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2022.103648_bib46","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.18632\/oncotarget.27265","article-title":"Multiplatform profiling of pancreatic neuroendocrine tumors: correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations","volume":"10","author":"Gong","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2022.103648_bib47","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1530\/EJE-18-0305","article-title":"Prognostic relevance of proliferation-related miRNAs in pancreatic neuroendocrine neoplasms","volume":"179","author":"Grolmusz","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/00365521.2018.1553061","article-title":"Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study","volume":"54","author":"Gudmundsdottir","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/PAP.0000000000000201","article-title":"Neoplasms of the neuroendocrine pancreas: an update in the classification, definition, and molecular genetic advances","volume":"26","author":"Guilmette","year":"2019","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib50","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12022-020-09611-8","article-title":"Alternative lengthening of telomeres and differential expression of endocrine transcription factors distinguish metastatic and non-metastatic insulinomas","volume":"31","author":"Hackeng","year":"2020","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib51","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-15-0119","article-title":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Heetfeld","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib52","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1210\/jc.2008-1300","article-title":"Glucagon cell adenomatosis: a newly recognized disease of the endocrine pancreas","volume":"94","author":"Henopp","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2022.103648_bib53","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s00535-014-0987-2","article-title":"Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?","volume":"50","author":"Hijioka","year":"2015","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib54","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-16-3135","article-title":"Rb loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: A Japanese multicenter pancreatic NEN-G3 study","volume":"23","author":"Hijioka","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103648_bib55","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1200\/JCO.2014.56.2082","article-title":"Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors","volume":"33","author":"Hobday","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib56","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1136\/gutjnl-2018-317233","article-title":"Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system","volume":"69","author":"Hong","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.critrevonc.2022.103648_bib57","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.molcel.2009.09.006","article-title":"Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation","volume":"35","author":"Huang","year":"2009","journal-title":"Mol. Cell."},{"key":"10.1016\/j.critrevonc.2022.103648_bib58","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1073\/pnas.1712262115","article-title":"MAFA missense mutation causes familial insulinomatosis and diabetes mellitus","volume":"115","author":"Iacovazzo","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.critrevonc.2022.103648_bib59","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib60","article-title":"Pancreatic neuroendocrine neoplasms: the latest surgical and medical treatment strategies based on the current World Health Organization classification","volume":"145","author":"Ishida","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib61","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/modpathol.2016.222","article-title":"SOX2 and Rb1 in esophageal small-cell carcinoma: their possible involvement in pathogenesis","volume":"30","author":"Ishida","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib62","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/MD.0b013e3182954af1","article-title":"Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1\/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors","volume":"92","author":"Ito","year":"2013","journal-title":"Medicine ((Baltimore))"},{"key":"10.1016\/j.critrevonc.2022.103648_bib63","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00535-014-0934-2","article-title":"Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis","volume":"50","author":"Ito","year":"2015","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib64","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1210\/en.2014-1966","article-title":"miR-144\/451 promote cell proliferation via targeting PTEN\/AKT pathway in insulinomas","volume":"156","author":"Jiang","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.critrevonc.2022.103648_bib65","first-page":"1683","article-title":"THBS2, a microRNA-744-5p target, modulates MMP9 expression through CUX1 in pancreatic neuroendocrine tumors","volume":"19","author":"Jiao","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2022.103648_bib66","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2022.103648_bib67","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1086\/302381","article-title":"Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis","volume":"64","author":"Jones","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.critrevonc.2022.103648_bib68","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cell.2008.12.002","article-title":"PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt","volume":"136","author":"Kawase","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2022.103648_bib69","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7150\/jca.13711","article-title":"The impact of PD-L1 expression in patients with metastatic GEP-NETs","volume":"7","author":"Kim","year":"2016","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib70","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12328-016-0655-6","article-title":"Neuroendocrine carcinoma of the pancreas with similar genetic alterations to invasive ductal adenocarcinoma","volume":"9","author":"Kimura","year":"2016","journal-title":"Clin. J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib71","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00247-016-3701-0","article-title":"Pancreatic tumors in children and young adults with tuberous sclerosis complex","volume":"47","author":"Koc","year":"2017","journal-title":"Pediatr. Radiol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib72","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.humpath.2018.03.018","article-title":"Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3","volume":"77","author":"Konukiewitz","year":"2018","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib73","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1530\/ERC-18-0100","article-title":"Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors","volume":"25","author":"Krauss","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib74","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4103\/sajc.sajc_364_18","article-title":"Clinical and epidemiological profile of neuroendocrine tumors: an experience from a regional cancer center from Western India","volume":"8","author":"Kulkarni","year":"2019","journal-title":"South Asian J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib75","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib76","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/annonc\/mdx078","article-title":"A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial","volume":"28","author":"Kulke","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib77","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1634\/theoncologist.12-5-535","article-title":"Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors","volume":"12","author":"Kunnimalaiyaan","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2022.103648_bib78","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib79","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00428-018-2366-5","article-title":"c-MYC amplification and c-myc protein expression in pancreatic acinar cell carcinomas. New insights into the molecular signature of these rare cancers","volume":"473","author":"La Rosa","year":"2018","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2022.103648_bib80","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1572-0241.1998.401_w.x","article-title":"Role of p53 tumor suppressor gene in pancreatic endocrine tumors of Chinese patients","volume":"93","author":"Lam","year":"1998","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/mp.53.3.133","article-title":"Telomerase activity in pancreatic endocrine tumours: a potential marker for malignancy","volume":"53","author":"Lam","year":"2000","journal-title":"Mol. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib82","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archderm.141.1.71","article-title":"Prevalence of neurofibromatosis 1 in German children at elementary school enrollment","volume":"141","author":"Lammert","year":"2005","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib83","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1399-0004.2011.01805.x","article-title":"Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex","volume":"82","author":"Larson","year":"2012","journal-title":"Clin Genet."},{"key":"10.1016\/j.critrevonc.2022.103648_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.critrevonc.2022.103648_bib85","first-page":"593","article-title":"Roles of long-non-coding RNAs in cancer therapy through the PI3K\/Akt signalling pathway","volume":"34","author":"Lee","year":"2019","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib86","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.cgh.2018.12.017","article-title":"Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States","volume":"17","author":"Lee","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib87","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-5-85","article-title":"Zollinger-Ellison syndrome associated with neurofibromatosis type 1: a case report","volume":"5","author":"Lee","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib88","article-title":"High expression of MicroRNA-196a indicates poor prognosis in resected pancreatic neuroendocrine tumor","volume":"94","author":"Lee","year":"2015","journal-title":"Medicine ((Baltimore))"},{"key":"10.1016\/j.critrevonc.2022.103648_bib89","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/humu.20605","article-title":"Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene","volume":"29","author":"Lemos","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.critrevonc.2022.103648_bib90","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1158\/1078-0432.CCR-12-3092","article-title":"MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls","volume":"19","author":"Li","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103648_bib91","doi-asserted-by":"crossref","first-page":"38755","DOI":"10.18632\/oncotarget.16333","article-title":"Significance of PI3K\/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2022.103648_bib92","series-title":"The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours of Endocrine Organs","first-page":"241","article-title":"Inherited tumour syndromes","author":"Lloyd","year":"2017"},{"key":"10.1016\/j.critrevonc.2022.103648_bib93","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"von Hippel-Lindau disease","volume":"361","author":"Lonser","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2022.103648_bib94","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.3748\/wjg.v26.i19.2305","article-title":"Pancreatic neuroendocrine tumors: a review of serum biomarkers, staging, and management","volume":"26","author":"Ma","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib95","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2265.2007.02934.x","article-title":"Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers","volume":"67","author":"Machens","year":"2007","journal-title":"Clin. Endocrinol. ((Oxf))"},{"key":"10.1016\/j.critrevonc.2022.103648_bib96","doi-asserted-by":"crossref","first-page":"R161","DOI":"10.1530\/JOE-17-0560","article-title":"Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium","volume":"236","author":"Mafficini","year":"2018","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib97","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ejhg.2010.175","article-title":"von Hippel-Lindau disease: a clinical and scientific review","volume":"19","author":"Maher","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.critrevonc.2022.103648_bib98","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2169\/internalmedicine.34.661","article-title":"Somatostatinoma of the pancreas associated with von Hippel-Lindau disease","volume":"34","author":"Maki","year":"1995","journal-title":"Intern. Med."},{"key":"10.1016\/j.critrevonc.2022.103648_bib99","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000487326","article-title":"A comprehensive assessment of the role of miRNAs as biomarkers in gastroenteropancreatic neuroendocrine tumors","volume":"107","author":"Malczewska","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.critrevonc.2022.103648_bib100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/boc.201500062","article-title":"Modulatory roles of microRNAs in the regulation of different signalling pathways in large bowel cancer stem cells","volume":"108","author":"Mamoori","year":"2016","journal-title":"Biol. Cell."},{"key":"10.1016\/j.critrevonc.2022.103648_bib101","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.2147\/CMAR.S174907","article-title":"Prognosis of patients with neuroendocrine tumor: a SEER database analysis","volume":"10","author":"Man","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.critrevonc.2022.103648_bib102","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2013.10.020","article-title":"Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors","volume":"146","author":"Marinoni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2022.103648_bib103","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.mrfmmm.2013.03.003","article-title":"Role of MUTYH in human cancer","volume":"743\u2013744","author":"Mazzei","year":"2013","journal-title":"Mutat Res."},{"key":"10.1016\/j.critrevonc.2022.103648_bib104","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41368-020-0084-8","article-title":"Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma","volume":"12","author":"Mei","year":"2020","journal-title":"Int. J. Oral Sci."},{"key":"10.1016\/j.critrevonc.2022.103648_bib105","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/gim.2012.51","article-title":"Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome","volume":"14","author":"Mester","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.critrevonc.2022.103648_bib106","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/MPA.0000000000001933","article-title":"Adult proinsulinomatosis associated with a MAFA germline mutation as a rare cause of recurrent hypoglycemia","volume":"50","author":"Mintziras","year":"2021","journal-title":"Pancreas"},{"key":"10.1016\/j.critrevonc.2022.103648_bib107","article-title":"BRAF mutated colorectal cancer: new treatment approaches","volume":"12","author":"Molina-Cerrillo","year":"2020","journal-title":"Cancers ((Basel))"},{"key":"10.1016\/j.critrevonc.2022.103648_bib108","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1210\/jc.2005-0540","article-title":"Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling","volume":"90","author":"Nakakura","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2022.103648_bib109","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4158\/EP10379.RA","article-title":"Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice","volume":"17","author":"Newey","year":"2011","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.critrevonc.2022.103648_bib110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1210\/jc.2015-3684","article-title":"Neuroendocrine tumor of the pancreas as a manifestation of cowden syndrome: a case report","volume":"101","author":"Neychev","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2022.103648_bib111","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.tranon.2018.08.005","article-title":"Chemotherapeutic treatments increase PD-L1 expression in esophageal squamous cell carcinoma through EGFR\/ERK activation","volume":"11","author":"Ng","year":"2018","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib112","first-page":"469","article-title":"BRAF mutation: Current and future clinical pathological applications in colorectal carcinoma","volume":"34","author":"Ng","year":"2019","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib113","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5009\/gnl.2012.6.3.287","article-title":"The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1","volume":"6","author":"Niina","year":"2012","journal-title":"Gut. Liver"},{"key":"10.1016\/j.critrevonc.2022.103648_bib114","first-page":"521","article-title":"Genetic analysis of von Hippel-Lindau disease","volume":"31","author":"Nordstrom-O'Brien","year":"2010","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.critrevonc.2022.103648_bib115","doi-asserted-by":"crossref","first-page":"E2404","DOI":"10.1073\/pnas.1319962111","article-title":"PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors","volume":"111","author":"Ohki","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2022.103648_bib116","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/ijms18010143","article-title":"Pancreatic neuroendocrine neoplasms: basic biology, current treatment strategies and prospects for the future","volume":"18","author":"Ohmoto","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2022.103648_bib117","first-page":"779","article-title":"Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors","volume":"24","author":"Oktay","year":"2019","journal-title":"J. Buon."},{"key":"10.1016\/j.critrevonc.2022.103648_bib118","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaad.2010.04.010","article-title":"Glucagon cell adenomatosis: a new entity associated with necrolytic migratory erythema and glucagonoma syndrome","volume":"65","author":"Otto","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib119","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/PAT.0b013e328360b61d","article-title":"Clinicopathological relevance of BRAF mutations in human cancer","volume":"45","author":"Pakneshan","year":"2013","journal-title":"Pathology"},{"key":"10.1016\/j.critrevonc.2022.103648_bib120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1530\/ERC-18-0244","article-title":"Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing","volume":"26","author":"Panarelli","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib121","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.critrevonc.2022.103648_bib122","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2022.103648_bib123","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1586\/17474124.2015.1092383","article-title":"Genetics of pancreatic neuroendocrine tumors: implications for the clinic","volume":"9","author":"Pea","year":"2015","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib124","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/SLA.0000000000003022","article-title":"Genetic analysis of small well-differentiated pancreatic neuroendocrine tumors identifies subgroups with differing risks of liver metastases","volume":"271","author":"Pea","year":"2020","journal-title":"Ann. Surg."},{"key":"10.1016\/j.critrevonc.2022.103648_bib125","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/00000478-200608000-00018","article-title":"Pancreatic endocrine tumors are a rare manifestation of the neurofibromatosis type 1 phenotype: molecular analysis of a malignant insulinoma in a NF-1 patient","volume":"30","author":"Perren","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib126","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(15)70136-1","article-title":"Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study","volume":"16","author":"Phan","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib127","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2265.2008.03324.x","article-title":"Multiple endocrine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcome","volume":"70","author":"Pieterman","year":"2009","journal-title":"Clin. Endocrinol. ((Oxf))"},{"key":"10.1016\/j.critrevonc.2022.103648_bib128","doi-asserted-by":"crossref","first-page":"R121","DOI":"10.1530\/ERC-13-0482","article-title":"Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis","volume":"21","author":"Pieterman","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10897-008-9187-7","article-title":"Cowden syndrome: a critical review of the clinical literature","volume":"18","author":"Pilarski","year":"2009","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.critrevonc.2022.103648_bib130","doi-asserted-by":"crossref","first-page":"R519","DOI":"10.1530\/ERC-19-0175","article-title":"The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours","volume":"26","author":"Pipinikas","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib131","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","article-title":"Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway","volume":"142","author":"Polivka","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2022.103648_bib132","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.pan.2019.03.002","article-title":"Patient characteristics and clinical outcomes following initial surgical intervention for MEN1 associated pancreatic neuroendocrine tumours: a systematic review and exploratory meta-analysis of the literature","volume":"19","author":"Ratnayake","year":"2019","journal-title":"Pancreatology"},{"key":"10.1016\/j.critrevonc.2022.103648_bib133","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2022.103648_bib134","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s11605-009-1123-0","article-title":"Periampullary and duodenal neoplasms in neurofibromatosis type 1: two cases and an updated 20-year review of the literature yielding 76 cases","volume":"14","author":"Relles","year":"2010","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.critrevonc.2022.103648_bib135","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(04)15957-6","article-title":"Von Hippel-Lindau disease","volume":"363","author":"Richard","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2022.103648_bib136","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib137","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1200\/JCO.2005.05.5194","article-title":"MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior","volume":"24","author":"Roldo","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib138","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/2159-8290.CD-15-0068","article-title":"A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics","volume":"5","author":"Sadanandam","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2022.103648_bib139","doi-asserted-by":"crossref","first-page":"R145","DOI":"10.1530\/ERC-19-0372","article-title":"Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature","volume":"27","author":"Sadowski","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib140","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1365-2265.2011.04227.x","article-title":"Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database","volume":"76","author":"Sakurai","year":"2012","journal-title":"Clin. Endocrinol. ((Oxf))"},{"key":"10.1016\/j.critrevonc.2022.103648_bib141","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1634\/theoncologist.2017-0144","article-title":"Phase II study of BEZ235 versus everolimus in patients with mammalian target of rapamycin inhibitor-na\u00efve advanced pancreatic neuroendocrine tumors","volume":"23","author":"Salazar","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2022.103648_bib142","doi-asserted-by":"crossref","first-page":"17812","DOI":"10.1038\/s41598-018-36129-1","article-title":"Analysis of expression of the PD-1\/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors","volume":"8","author":"Sampedro-N\u00fa\u00f1ez","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2022.103648_bib143","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.ejhg.5201402","article-title":"Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex","volume":"13","author":"Sancak","year":"2005","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.critrevonc.2022.103648_bib144","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2022.103648_bib145","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(17)30171-7","article-title":"Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial","volume":"18","author":"Schreuer","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib146","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12022-020-09605-6","article-title":"Gallbladder mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) arising in intracholecystic papillary neoplasm: clinicopathologic and molecular analysis of a case and review of the literature","volume":"31","author":"Sciarra","year":"2020","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib147","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncy.22073","article-title":"Advances in the cytologic diagnosis of gastroenteropancreatic neuroendocrine neoplasms","volume":"126","author":"Sigel","year":"2018","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib148","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/1078-0432.CCR-16-1113","article-title":"Alternative lengthening of telomeres and loss of DAXX\/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors","volume":"23","author":"Singhi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103648_bib149","doi-asserted-by":"crossref","first-page":"E783","DOI":"10.1210\/jc.2014-4405","article-title":"Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations","volume":"100","author":"Sipos","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2022.103648_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2020.103873","article-title":"Revised Danish guidelines for the cancer surveillance of patients with Cowden Syndrome","volume":"63","author":"Smerdel","year":"2020","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.critrevonc.2022.103648_bib151","first-page":"20","article-title":"Multifocal insulinoma secondary to insulinomatosis: persistent hypoglycaemia despite total pancreatectomy","volume":"2020","author":"Snaith","year":"2020","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"10.1016\/j.critrevonc.2022.103648_bib152","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1002\/cam4.2259","article-title":"Clinical analysis of 547 patients with neuroendocrine tumors in a Chinese population: a single-center study","volume":"8","author":"Song","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2022.103648_bib153","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ecl.2018.04.007","article-title":"Molecular genetic studies of pancreatic neuroendocrine tumors: new therapeutic approaches","volume":"47","author":"Stevenson","year":"2018","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.critrevonc.2022.103648_bib154","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/1078-0432.CCR-10-1215","article-title":"Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability","volume":"17","author":"Stolz","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103648_bib155","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/ejhg.2016.93","article-title":"The biological effects and clinical implications of BRCA mutations: where do we go from here?","volume":"24","author":"Stoppa-Lyonnet","year":"2016","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.critrevonc.2022.103648_bib156","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2022.103648_bib157","doi-asserted-by":"crossref","first-page":"13166","DOI":"10.1038\/s41598-018-31383-9","article-title":"Profiling the tumour immune microenvironment in pancreatic neuroendocrine neoplasms with multispectral imaging indicates distinct subpopulation characteristics concordant with WHO 2017 classification","volume":"8","author":"Takahashi","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2022.103648_bib158","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/cas.13235","article-title":"A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors","volume":"108","author":"Takikawa","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2022.103648_bib159","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/PAS.0000000000000662","article-title":"A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas","volume":"40","author":"Tang","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib160","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1158\/1078-0432.CCR-15-0548","article-title":"Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas","volume":"22","author":"Tang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103648_bib161","first-page":"87","article-title":"Assays for predicting and monitoring responses to lung cancer immunotherapy","volume":"12","author":"Teixid\u00f3","year":"2015","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.critrevonc.2022.103648_bib162","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2022.103648_bib163","first-page":"2249","article-title":"Global microRNA profiling of pancreatic neuroendocrine neoplasias","volume":"34","author":"Thorns","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2022.103648_bib164","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4158\/EP10376.RA","article-title":"Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature","volume":"17","author":"Tonelli","year":"2011","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.critrevonc.2022.103648_bib165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005637","article-title":"Mosaic and intronic mutations in TSC1\/TSC2 explain the majority of TSC patients with No mutation identified by conventional testing","volume":"11","author":"Tyburczy","year":"2015","journal-title":"PLoS Genet."},{"key":"10.1016\/j.critrevonc.2022.103648_bib166","doi-asserted-by":"crossref","first-page":"e949","DOI":"10.1097\/SLA.0000000000003624","article-title":"Immunohistochemically detected expression of ATRX, TSC2, and PTEN predicts clinical outcomes in patients with grade 1 and 2 pancreatic neuroendocrine tumors","volume":"274","author":"Uemura","year":"2021","journal-title":"Ann. Surg."},{"key":"10.1016\/j.critrevonc.2022.103648_bib167","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/cncy.21857","article-title":"Alternative lengthening of telomeres and ATRX\/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors","volume":"125","author":"VandenBussche","year":"2017","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib168","doi-asserted-by":"crossref","first-page":"20","DOI":"10.15586\/jkcvhl.2017.88","article-title":"A review of Von Hippel-Lindau syndrome","volume":"4","author":"Varshney","year":"2017","journal-title":"J. Kidney Cancer VHL"},{"key":"10.1016\/j.critrevonc.2022.103648_bib169","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3390\/molecules19022458","article-title":"Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract","volume":"19","author":"Vicentini","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.critrevonc.2022.103648_bib170","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/bjc.2016.229","article-title":"Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study","volume":"115","author":"Vijayvergia","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib171","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2174\/156800961407140926105634","article-title":"The important roles of miR-205 in normal physiology, cancers and as a potential therapeutic target","volume":"14","author":"Vosgha","year":"2014","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.critrevonc.2022.103648_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109813","article-title":"Sex-biased islet \u03b2 cell dysfunction is caused by the MODY MAFA S64F variant by inducing premature aging and senescence in males","volume":"37","author":"Walker","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2022.103648_bib173","first-page":"448","article-title":"The clinical significance of PD-L1\/PD-1 expression in gastroenteropancreatic neuroendocrine neoplasia","volume":"49","author":"Wang","year":"2019","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.critrevonc.2022.103648_bib174","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/modpathol.2012.143","article-title":"Heterogeneity in signaling pathways of gastroenteropancreatic neuroendocrine tumors: a critical look at notch signaling pathway","volume":"26","author":"Wang","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib175","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1158\/0008-5472.CAN-10-3221","article-title":"The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization","volume":"71","author":"Wang","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103648_bib176","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2174\/138920310791824039","article-title":"Notch signaling proteins: legitimate targets for cancer therapy","volume":"11","author":"Wang","year":"2010","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.critrevonc.2022.103648_bib177","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1172\/JCI65634","article-title":"Atrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span","volume":"123","author":"Watson","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2022.103648_bib178","doi-asserted-by":"crossref","first-page":"a003814","DOI":"10.1101\/mcs.a003814","article-title":"Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor","volume":"5","author":"Williamson","year":"2019","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"10.1016\/j.critrevonc.2022.103648_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2019.101598","article-title":"Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia","volume":"63","author":"Wyld","year":"2019","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib180","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1158\/1078-0432.CCR-18-2994","article-title":"Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, single-arm, open-label, phase Ib\/II trial","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103648_bib181","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib182","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/PAS.0b013e3182417d36","article-title":"Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors","volume":"36","author":"Yachida","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib183","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib184","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103648_bib185","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2022.103648_bib186","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1530\/ERC-18-0332","article-title":"Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials","volume":"26","author":"Yao","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103648_bib187","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/MPA.0000000000001562","article-title":"Malignant insulinoma is largely derived from nonfunctioning pancreatic neuroendocrine tumors: a contemporary view","volume":"49","author":"Yu","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.critrevonc.2022.103648_bib188","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MPA.0b013e31815ceb23","article-title":"Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature","volume":"36","author":"Yu","year":"2008","journal-title":"Pancreas"},{"key":"10.1016\/j.critrevonc.2022.103648_bib189","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ajpath.2019.11.007","article-title":"miR-431 promotes metastasis of pancreatic neuroendocrine tumors by targeting DAB2 interacting protein, a ras GTPase activating protein tumor suppressor","volume":"190","author":"Zhang","year":"2020","journal-title":"Am. J. Pathol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822000725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822000725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:43:16Z","timestamp":1760902996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822000725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":189,"alternative-id":["S1040842822000725"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103648","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103648","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103648"}}